RxDoctor Payments DataLook up a doctor →

Mary Drey, MD

Internal Medicine · Lincoln, NENPI 1285792903

Payments from drug & device makers

$6,198in general payments, 2019–2025

Across 450 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$871
  • Amgen$825
  • Lilly USA, LLC$495
  • GSK$326
  • Astellas Pharma US Inc$238
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$6,10498%
  • Education$942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,198 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$49,188
Medicare patients
151
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$45,757
XareltoRivaroxaban52$36,427
FarxigaDapagliflozin Propanediol33$26,537
TrulicityDulaglutide13$15,510
Aimovig AutoinjectorErenumab-Aooe18$13,148
JardianceEmpagliflozin17$12,984
OxycontinOxycodone Hcl19$8,271
MyrbetriqMirabegron15$7,613
NamzaricMemantine Hcl/Donepezil Hcl13$7,422
LinzessLinaclotide13$6,774
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen167$6,066
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$5,980
Oxycodone Hcl38$5,594
MovantikNaloxegol Oxalate14$5,144
SynthroidLevothyroxine Sodium54$4,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$871$45,75749 claims
Johnson & JohnsonXarelto$40$36,42752 claims
AstraZenecaFarxiga$191$26,53733 claims
AbbVieNamzaric, Linzess, Synthroid$1,158$19,19080 claims
Lilly USA, LLCTrulicity$495$15,51013 claims
Boehringer IngelheimJardiance$155$12,98417 claims
Astellas Pharma US IncMyrbetriq$238$7,61315 claims
GSKAnoro Ellipta$326$5,98016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →